Psoriasis | Treatment Algorithms: Claims Data Analysis | Pediatric Psoriasis | US | 2021

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management of pediatric psoriasis is more challenging owing to limited treatments approved for children. Although topical corticosteroids continue to be the mainstay of pediatric psoriasis treatment, there is an increase in biologics use owing to the more frequent and severe adverse events associated with the long-term use of topical corticosteroids in children. Use of conventional systemics also appears to be on the decline, further underscoring a growing need for treatments with more-acceptable safety profiles.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
• How have biologics such as Cosentyx, Enbrel, Humira, Stelara, Taltz, and Tremfya been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of pediatric psoriasis patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of pediatric patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of pediatric psoriasis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated pediatric patients with psoriasis?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Amgen, Bausch Health, Eli Lilly, Janssen, Novartis

Key drugs: Cosentyx, Elidel, Enbrel, Humira, Stelara, Taclonex, Taltz, Tremfya